CIRCULATING CANCER-ASSOCIATED-MACROPHAGE-LIKE CELLS (CAMLs) AND CIRCULATING TUMOR CELLS EVALUATED IN A DOUBLE-BLIND STUDY AS DIAGNOSTIC BIOMARKERS IN THE BLOOD FOR PATIENTS WITH INDETERMINATE LUNG NODULES

On November 17, 2026 Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a liquid biopsy company focused on innovative diagnostics for cancer, reported a double-blind study with the Fox Chase Cancer Center and the University of Pennsylvania to determine if the presence, type or size of its Cancer-Associated-Macrophage-Like Cell (CAML) biomarker, as well as epithelial-mesenchymal transition circulating tumor cells (EMT CTCs) could help to identify the presence of malignancy in patients with unknown indeterminate pulmonary nodules.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, which appeared in the Journal of Clinical Oncology – Precision Oncology 10:e2501142 in July 2026, is titled: Pragmatic, Multicenter, Double-Blind Evaluation of Circulating Cancer-Associated Macrophage-Like Cells for Detection of Cancer in Indeterminate Pulmonary Nodules, enrolled 203 patients with indeterminate nodules (0.8-3.0 cm) with no prior diagnosis of cancer.

Overall, CAMLs were detected in 45% of all evaluable patient samples (n=191), while EMT CTCs were detected in 20%. For the detection of patients with any malignancy, CAML positive predictive value (PPV) and negative predictive value (NPV) were 27.9% and 61.9% respectively with a sensitivity of 37.5% and specificity of 51.2%. However, while CAMLs or EMT CTCs alone could not help to differentiate between benign and malignant indeterminate nodules, when CAMLs and EMT CTCs were present in conjunction, the results showed that specificity in identifying malignancy improved to 90.6%.

CAMLs are large (>50 microns), myeloid polyploid cells that originate from the tumor site and are found circulating in the blood of patients with a variety of cancers – even in the earliest stages of disease. EMT CTCs are tumor cells found circulating in the blood of patients. Studies have shown that CAMLs and EMT CTCs have the potential to track cancer progression and therapy response and are particularly associated with disease progression.

(Press release, Creatv Bio, NOV 17, 2026, View Source [SID1234674891])

Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer

On November 17, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eikon plans to initiate a Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability and preliminary efficacy of EIK1006 in participants with metastatic androgen-pathway-modulation-resistant prostate cancer (mAPMRPC) that has progressed on established anti-hormonal therapy. Formerly known as metastatic castration-resistant prostate cancer (mCRPC), mAPMRPC remains an area of high unmet need because resistance to established anti-hormonal therapy is common and limits durable benefit. EIK1006 is intended to address resistance driven by androgen receptor (AR) pathway alterations, including AR amplification and ligand-binding domain mutations. Eikon expects to begin dosing participants in this study in 2027, with preliminary safety and efficacy data to be available in the second half of 2027.

"IND clearance for EIK1006 is an important milestone for Eikon and for patients with advanced metastatic prostate cancer, where resistance to current androgen receptor-directed therapies remains a significant challenge. EIK1006’s progression into the clinic reflects the strength of our proprietary drug discovery platform and our ability to nominate novel chemical material and rapidly advance them into human studies," said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. "We look forward to initiating clinical evaluation of EIK1006 and to continuing to translate our platform into potential new medicines for patients with significant unmet need."

About EIK1006
EIK1006 is an internally-derived clinical candidate and is being investigated as a potential next-generation androgen receptor (AR) antagonist with activity against wild type and multiple clinically important genetic variants of AR that emerge during treatment with conventional AR antagonists. Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling.

(Press release, Eikon Therapeutics, NOV 17, 2026, View Source [SID1234674844])

Cerus Corporation to Participate in Upcoming Investor Conferences

On November 17, 2026 Cerus Corporation (Nasdaq: CERS) reported that members of the Company’s management will participate in the following upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2026 Global Healthcare Conference
Format: One-on-one meetings
Date: Tuesday, December 1, 2026
Location: Miami, Florida

Piper Sandler 38th Annual Healthcare Conference
Format: One-on-one meetings
Date: Wednesday, December 2, 2026
Location: New York, New York

(Press release, Cerus, NOV 17, 2026, View Source [SID1234674874])

Racura Oncology’s RC220 Matches RC110 Drug Exposure in Nonclinical Bridging Study, Linking RC220 to Prior Clinical Experience in AML

On November 17, 2026 Racura Oncology Ltd (ASX: RAC) ("Racura" or the "Company"), a late clinical-stage biopharmaceutical company developing new small molecule-based approaches to cancer treatment focused on inhibiting MYC gene expression, reported results from a Good Laboratory Practice (GLP) nonclinical pharmacokinetic (PK) bridging study showing that RC220, the Company’s proprietary formulation of (E,E)-bisantrene, delivers systemic drug exposure equivalent to RC110, the earlier formulation used in two investigator-sponsored clinical trials in relapsed or refractory (R/R) acute myeloid leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the study, conducted in Beagle dogs (n = 6), the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of RC220 to RC110 exposure for both peak plasma concentration (Cmax) and total exposure (area under the concentration–time curve, AUC) fell within the pre-specified equivalence range of 0.80–1.25 on each of three consecutive dosing days, with GMRs ranging from 0.971 to 1.057. These nonclinical data support applying the established RC110 clinical dataset and dosing levels to the clinical development of RC220, including the Phase 2b/3 EMILI trial in AML.

Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said: "This nonclinical study was designed to answer a critical question for our RC220 clinical programs: does RC220 deliver the same drug exposure as RC110? The results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene. The findings provide an important bridge to the clinical experience with RC110, which produced a 40% response rate in two separate clinical trials in heavily pretreated AML patients. The bridging study results support our plans to evaluate RC220 in patients with AML in the EMILI trial as well as our HARNESS and CPACS clinical programs. I wish to thank the Racura team and our study partners for the careful execution of this important work."

Study Design and Results

RC110 and RC220 contain the same active ingredient, (E,E)-bisantrene, and differ only in their formulation excipients. RC220 was developed to allow (E,E)-bisantrene to be given through a peripheral vein, rather than requiring a central venous line.

The study used a two-period crossover design in which each male Beagle dog received once-daily intravenous doses (30-minute infusion) of RC110 and RC220 for three consecutive days, in random order and separated by a five-day washout, so that each animal served as its own control. Repeat daily dosing was examined because RC110 was given as a daily infusion over several consecutive days in the earlier AML trials, and the same approach is planned for RC220.

Equivalence was assessed using the statistical approach described in US Food and Drug Administration (FDA) and European Medicines Agency (EMA) bioequivalence guidance, in which the 90% CI of the GMR must lie entirely within 0.80–1.25. All six intervals met this criterion, with the widest being 0.841–1.179 for Day 1 Cmax (Figure 1).

The dog is a standard species for nonclinical PK and safety studies and was one of the two species used in the GLP toxicology program for RC220. The doses used were well below the level that causes harm, and no animal was harmed in the study. These results characterize drug exposure in the bloodstream of dogs; they do not measure anticancer activity. The safety and efficacy of RC220 in patients with AML remain to be established in clinical trials.

Significance for the RC220 Clinical Programs

RC110 was used in two investigator-sponsored clinical trials in R/R AML conducted at Sheba Medical Center, Israel. In a Phase 2 trial, RC110 given as a single agent produced an overall response rate (complete or partial responses) of 40% in 10 patients (Canaani et al., Eur J Haematol 2021). In a Phase 1b/2 trial, RC110 combined with fludarabine and clofarabine produced a response in 6 of 15 evaluable patients (Danylesko et al., Br J Haematol 2025). These results underpin Racura’s plan to advance RC220 in AML through the Phase 2b/3 EMILI trial.

RC220 is already being administered to patients through a peripheral vein in the Phase 1 CPACS solid tumor trial and the Phase 1 HARNESS lung cancer trial. While the bridging study results are not essential for these trials, they may help accelerate dose escalation or progression to later-stage trials. Racura will use the results to support regulatory submissions for AML and other clinical indications.

About RC220 & (E,E)-bisantrene

RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene is a clinically validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC and downstream pathways.

(Press release, Racura Oncology, NOV 17, 2026, View Source [SID1234674892])

Isomorphic Labs announces $5 Billion Series C funding

On November 17, 2026 Isomorphic Labs, an AI company focussed on designing and developing new medicines, reported a $5 Billion Series C financing round. The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors, with continued significant investment from Alphabet. The round also included participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Isomorphic is scaling its proprietary drug design engine (IsoDDE) and therapeutic candidate pipeline designed with AI to deliver the next generation of medicines. IsoDDE unifies a suite of foundational simulation AI models that natively work across multiple therapeutic areas and drug modalities. IsoDDE explores vast chemical spaces to enable Isomorphic’s world-class team to design, refine, and deliver exquisitely engineered molecules with optimal drug-like properties.

The breadth and precision of the simulation models within IsoDDE push predictions towards experimental accuracy and provide a suite of capabilities to advance innovative medicines. Combined with powerful proprietary agents that navigate and reason over highly complex biological systems, these models directly and repeatedly translate into advancements across the company’s multi-modality pipeline of therapeutic candidates, addressing some of the most challenging problems in the industry. This momentum is yielding positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry.

This new capital accelerates the scientific breakthroughs and proprietary AI advances being made by Isomorphic. The company will continue to mature IsoDDE as well as expand deeper into new biology with highly advanced models. To deliver new and transformative classes of therapeutics, Isomorphic is creating a partner ecosystem to advance the understanding of mechanistic disease biology. In parallel, the company is building the global infrastructure required to power the future of AI-led bioengineering. Proceeds will also support the company’s continued build of scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials.

"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said Sir Demis Hassabis, Founder and CEO of Isomorphic Labs. "Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."

"Every week we are making repeatable scientific advancements enabled by our models," said Max Jaderberg, President of Isomorphic Labs. "These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades. We are translating our discoveries directly into potential life-changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing."

"Discovering and developing new medicines is an optimization challenge of almost infinite scale," said Neil Mehta, Founder and Managing Partner of Greenoaks. "Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicines. We believe Demis, Max, and the Isomorphic team are building the future of AI-led drug discovery and we are proud to partner with them on this essential mission."

"Isomorphic Labs is building foundational technology for the future of medicine," said Konstantine Buhler, Partner at Sequoia Capital. "It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine."

(Press release, Isomorphic Labs, NOV 17, 2026, View Source [SID1234674944])